Physician profile
Yuting Xiong
NPI 1447209895
$5,535.92
in general payments reported to CMS, 2019-2025
35 companies · $646 in 2025
The $646 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,730 · 2020: $647 · 2021: $758 · 2022: $581 · 2023: $611 · 2024: $563 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $834.44 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $790.73 | 2019-2023 | Xtampza |
| Abbvie INC. | $470.59 | 2022-2025 | Qulipta, Ubrelvy |
| Depuy Synthes Sales INC. | $413.89 | 2020-2025 | Monovisc, Orthovisc |
| Tersera Therapeutics LLC | $356.63 | 2019-2025 | Prialt |
| Pfizer INC. | $296.93 | 2020-2023 | |
| Fidia Pharma USA INC. | $290.03 | 2019-2023 | Triluron, Hymovis |
| Takeda Pharmaceuticals U.S.A., INC. | $287.70 | 2023-2025 | Entyvio |
| Medtronic, INC. | $175.14 | 2023-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Redhill Biopharma INC. | $144.85 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $124.04 | 2022-2023 | Lyvispah |
| Orexo US, INC. | $113.99 | 2020-2021 | |
| Nevro Corp. | $99.25 | 2019-2021 | |
| Merz North America, INC. | $97.81 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.69 | 2019-2025 | Relistor |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $71.15 | 2024-2025 | Ibsrela |
| Indivior INC. | $71.03 | 2019 | |
| Abbott Laboratories | $67.89 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $67.60 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $66.89 | 2021-2025 | Euflexxa |
| Avanos Medical | $66.16 | 2024-2025 | Trivisc Sodium Hyaluronate, Genvisc 850 Sodium Hyaluronate |
| Daiichi Sankyo INC. | $64.74 | 2019 | |
| Scilex Pharmaceuticals INC. | $61.99 | 2019-2022 | |
| Sentynl Therapeutics, INC. | $61.33 | 2019 | |
| Lilly USA, LLC | $42.45 | 2021-2022 | |
| Bioventus LLC | $42.28 | 2019-2021 | |
| Protega Pharmaceutials INC | $42.23 | 2023 | Roxybond |
| Eisai INC. | $39.21 | 2020 | |
| Grt US Holding, INC. | $37.29 | 2020 | |
| Biodelivery Sciences International, INC. | $33.97 | 2019 | |
| Halozyme INC | $31.20 | 2024 | Hylenex Recombinant |
| Vertex Pharmaceuticals Incorporated | $25.43 | 2025 | |
| Kaleo, INC. | $20.41 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.43 | 2022 | |
| Allergan, INC. | $17.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuting Xiong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.